SCHEDULE 13D/A

LAKESHORE BIOPHARMA CO LTD

Ordinary Shares, par value $0.0002 per share · CUSIP: G9845F208

Event date: 2026-02-04

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• Huaqin Xue

  Shares: 21,021,332.00 · Class: 51.0%

• Crystal Peak Holdings Inc.

  Shares: 21,021,332.00 · Class: 51.0%

• Crystal Peak Investment Inc.Reported CIK 0002078050

  Shares: 21,021,332.00 · Class: 51.0%

• Dave Liguang Chenn

  Shares: 462,760.00 · Class: 1.1%

• Oceanpine Investment Fund II LP

  Shares: 410,560.00 · Class: 1.0%

• Oceanpine Capital Inc.

  Shares: 52,200.00 · Class: 0.1%

• Adjuvant Capital Management, L.L.C.

  Shares: 290,298.00 · Class: 0.70%

• Adjuvant Capital GP, L.P.

  Shares: 290,298.00 · Class: 0.70%

• Adjuvant Global Health Technology Fund, L.P.

  Shares: 243,630.00 · Class: 0.59%

• Adjuvant Global Health Technology Fund DE, L.P.

  Shares: 46,668.00 · Class: 0.11%

• MSA China Growth Fund II GP, LLC

  Shares: 112,904.00 · Class: 0.27%

• MSA Growth Fund II, L.P.

  Shares: 112,904.00 · Class: 0.27%

• Superstring Capital Management LP

  Shares: 30,792.00 · Class: 0.07%

• Superstring Capital Master Fund LP

  Shares: 30,792.00 · Class: 0.07%

• Epiphron Capital (Hong Kong) Limited

  Shares: 70,083.00 · Class: 0.17%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.